Vax spin-off / partnership

Not sure if this was shared already. Underwhelming results and a bad IPO market means immunotherapies to stay on the books (for now). Hope this doesn't mean we have to progress this through another phase to make a sale. Wonder what we can get for it as it stands - my view is that we are too small to play in vax development (need a large and well diversified portfolio).

https://invivo.pharmamedtechbi.com/IV005144/New-Future-For-Admedus-Immunotherapies--Not-Yet

New Future For Immunotherapies? – Not Yet
IN VIVO / 07/17/17
Admedus own 72% of Admedus Immunotherapies (AI), a subsidiary that has two major vaccines in
development. ( "Marketing Efforts Pay Off As Admedus Ups CardioCel Centers By 50" "In Vivo" )
The company is mulling over future strategies for the subsidiary, given its wish to focus on medtech
– "the main event." Paterson says, "We always said the strategy was to spin it off, or partner it out,
but the results have slowed that down and that makes it more problematic to do an IPO." In addition,
it's a bad market for an IPO right now, he adds.
The results he refers to are non-statistically powered small Phase IIa HSV study findings. There
were no major surprises in what Paterson described as interesting results. The market had assumed
and expected more however, although Paterson stresses that the study had been non-statistically
powered at the outset. The HSV vaccine is good, but may be a decade down the track. As well as
that, Admedus has an RNA vaccine program focusing on HPV and certain cancer types. It has a
collaboration with RANA (formerly with Shire). Other projects are in negotiation.
Admedus is still looking at both options – a public or private sale, or an IPO, and would take an
equity investment in the IPO. "Ideally, we'd be a medtech company and at the least, a shareholder
in immunotherapies, with no management input, says Paterson. “I would probably step away as
chairman of that board."